



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of Precautions

Warfarin potassium

August 3, 2017

Non-proprietary name

Warfarin potassium

Safety measure

Precautions should be revised in the package insert.

In the Clinically Significant Adverse Reactions subsection of the Adverse Reactions section, the following text should be added (underlined parts are revised):

Calciphylaxis:

Calciphylaxis, which is characterized by painful skin ulceration surrounded with painful purpura as well as calcification of small to medium arteries of subcutaneous adipose tissues or dermis may occur and could lead to sepsis in some cases. Patients should be carefully monitored and if such abnormalities are observed, administration of this drug should be discontinued and appropriate measures should be taken.